Praxbind, specific reversal agent for Pradaxa, available nationwide
RIDGEFIELD, Conn. — Boehringer Ingelheim announced that Praxbind (idarucizumab), a specific reversal agent for Pradaxa (dabigatran etexilate mesylate), is now stocked in 3,200 hospitals in all 50 states. This represents a significant increase in the availability of Praxbind since March 2016, when it was stocked in 2,200 institutions. Healthcare providers and patients can quickly search
